Dyslipidemia Pipeline Review, H2 2018 [Report Updated: 21082018] Prices from USD $2000

12:09 EDT 13 Oct 2018 | BioPortfolio Report Blog

Dyslipidemia Pipeline Review, H2 2018


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia Pipeline Review, H2 2018, provides an overview of the Dyslipidemia Metabolic Disorders pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" lowdensity lipoprotein LDL cholesterol and the triglyceride concentrations, and a decrease in the "good" highdensity lipoprotein HDL cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dyslipidemia Metabolic Disorders, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia Metabolic Disorders pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 29, 15, 16, 36, 7 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia Metabolic Disorders pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia Metabolic Disorders.

The pipeline guide reviews pipeline therapeutics for Dyslipidemia Metabolic Disorders by companies and universities/research institutes based on information derived from company and industryspecific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.

The pipeline guide reviews key companies involved in Dyslipidemia Metabolic Disorders therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyslipidemia Metabolic Disorders therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia Metabolic Disorders

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.

Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dyslipidemia Metabolic Disorders.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dyslipidemia Metabolic Disorders pipeline depth and focus of Indication therapeutics.

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Dyslipidemia Pipeline Review, H2 2018 [Report Updated: 21082018] Prices from USD $2000


More From BioPortfolio on "Dyslipidemia Pipeline Review, H2 2018 [Report Updated: 21082018] Prices from USD $2000"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is prescribed to lower cholesterol and triglycerides in the the...